How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

1,228 results for

Mean Corpuscular Volume

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

161. A Study to Evaluate the Effect of Itraconazole on the Pharmacokinetics (PK) of Nemiralisib

laboratory parameters [ Time Frame: Up to 41 days ] Hematology parameters will be analyzed as a measure of safety including platelet count, red blood cell (RBC) count, hemoglobin, hematocrit, mean corpuscular volume, mean corpuscular hemoglobin, percent reticulocytes, neutrophils, lymphocytes, monocytes, eosinophils and basophils. Number of subjects with abnormal values for urinalysis [ Time Frame: Up to 30 days ] Urinalysis parameters will be analyzed including specific gravity. The dipstick method (...) studies before adding more. A Study to Evaluate the Effect of Itraconazole on the Pharmacokinetics (PK) of Nemiralisib The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT03398421 Recruitment Status : Completed First Posted : January 12, 2018 Last Update Posted : January 15, 2019 Sponsor: GlaxoSmithKline

2018 Clinical Trials

162. Repeat Dose Study of GSK3772847 in Participants With Moderate to Severe Asthma With Allergic Fungal Airway Disease (AFAD)

in persistent disability/incapacity, congenital anomaly/birth defect or any other situation according to medical or scientific judgment. Number of participants with abnormal hematology parameters [ Time Frame: Up to Day 172 ] Laboratory assessment for hematology parameters will include Platelet count, hemoglobin, Red blood cell (RBC) count, hematocrit, Red blood cell distribution width (RDW), RBC indices like mean corpuscular volume (MCV), mean corpuscular hemoglobin (MCH) and mean corpuscular hemoglobin (...) number of saved studies (100). Please remove one or more studies before adding more. Repeat Dose Study of GSK3772847 in Participants With Moderate to Severe Asthma With Allergic Fungal Airway Disease (AFAD) The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. of clinical studies and talk to your health care provider before participating. Read our for details

2018 Clinical Trials

163. Pharmacokinetic Study of Oral Gepotidacin (GSK2140944) in Subjects With Uncomplicated Urinary Tract Infection (Acute Cystitis)

hemoglobin (MCH) [ Time Frame: Baseline and up to Day 13 ] Blood samples will be collected to assess change from Baseline in MCH. Change from Baseline in mean corpuscular volume (MCV) [ Time Frame: Baseline and up to Day 13 ] Blood samples will be collected to assess change from Baseline in MCV. Change from Baseline in hematocrit level [ Time Frame: Baseline and up to Day 13 ] Blood samples will be collected to assess change from Baseline in hematocrit level. Change from Baseline in red blood cell (RBC (...) machine. Change from Baseline in neutrophil, lymphocyte, monocyte, eosinophil, basophil and platelet count [ Time Frame: Baseline and up to Day 13 ] Blood samples will be collected to assess change from Baseline in neutrophil, lymphocyte, monocyte, eosinophil, basophil and platelet count. Change from Baseline in hemoglobin level [ Time Frame: Baseline and up to Day 13 ] Blood samples will be collected to assess change from Baseline in hemoglobin level. Change from Baseline in mean corpuscular

2018 Clinical Trials

164. Effects of Exercise on Physical Fitness Among Hemodialysis Patients With Chronic Kidney Disease

and the states closest to death. Change from baseline in Mental and health status (level of anxiety) at 6 month [ Time Frame: Baseline and 6 month ] the State-Trait Anxiety Inventory (STAI), The score range ranges from 0 to 60 points, so that high scores reflect greater anxiety. The scores obtained are transformed into decatypes (10 decatypes). Hemogram and Biochemical values , (hemoglobin, hematocrit and mean corpuscular volume ) [ Time Frame: Baseline ] Red blood cells, hemoglobin, hematocrit and mean (...) corpuscular volume were determined from whole blood anticoagulated with EDTA in a Sysmex XI-1000i hematological analyzer. with normal values for hemoglobin 14± 2 (g/dL) for women and of 16± 2 (g/dL) for men, for hematocrit 42± 5 % for women and of 47± 6 % for men and for corpuscular volumen 90 ± 7 (fL) for women and for men. Hemogram and Biochemical values (Iron, albumin, calcium and phosporus) [ Time Frame: Baseline ] Iron, albumin, calcium and phosphorus were made by spectrophotometry from serum

2018 Clinical Trials

165. A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AZD8233 in Healthy Male Subjects With Increased Elevated LDL-C Levels.

as a variable of safety and tolerability of AZD8233 following SC administration of single ascending doses. Laboratory assessments: Haematology - Haematocrit (HCT) [ Time Frame: From screening to 4 month follow-up. ] To assess HCT (volume percentage of RBC in blod) as a variable of safety and tolerability of AZD8233 following SC administration of single ascending doses. Laboratory assessments: Haematology - Mean corpuscular volume (MCV) [ Time Frame: From screening to 4 month follow-up. ] To assess MCV (...) as a variable of safety and tolerability of AZD8233 following SC administration of single ascending doses. Laboratory assessments: Haematology - Mean corpuscular hemoglobin (MCH) [ Time Frame: From screening to 4 month follow-up. ] To assess MCH as a variable of safety and tolerability following SC administration of single ascending doses. Laboratory assessments: Haematology - Mean corpuscular hemoglobin concentration (MCHC) [ Time Frame: From screening to 4 month follow-up. ] To assess MCHC as a variable

2018 Clinical Trials

166. A Study to Investigate the Efficacy and Safety of Two Doses of GSK2857916 in Subjects With Multiple Myeloma Who Have Failed Prior Treatment With an Anti-CD38 Antibody

[ Time Frame: Every 3 weeks up to 2 years ] Overall survival is defined as the time from first dose until death due to any cause. Number of subjects with abnormal hematology parameters [ Time Frame: Every 3 weeks up to 2 years ] Laboratory assessment for hematology parameters will include Platelet count, hemoglobin (Hgb), Red blood cell (RBC) count, hematocrit, reticulocyte count, RBC indices like mean corpuscular volume (MCV), mean corpuscular hemoglobin (MCH), and mean corpuscular hemoglobin (...) x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. A Study to Investigate the Efficacy and Safety of Two Doses of GSK2857916 in Subjects With Multiple Myeloma Who Have Failed Prior Treatment With an Anti-CD38 Antibody The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been

2018 Clinical Trials

167. Bioequivalence Study Between Levocetirizine Oral Disintegrating Tablet (ODT) and Levocetirizine Immediate Release Tablet (IRT)

: Up to Day 18 ] Laboratory assessment for hematology parameters will include Platelet count, hemoglobin, Red blood cell (RBC) count, hematocrit, RBC indices like mean corpuscular volume (MCV), mean corpuscular hemoglobin (MCH) and percentage reticulocytes. White blood cell (WBC) count with differential will include neutrophils, lymphocytes, monocytes, eosinophils and basophils. Number of subjects with abnormal hematology parameters: Part 2 [ Time Frame: Up to Day 18 ] Laboratory assessment (...) the maximum number of saved studies (100). Please remove one or more studies before adding more. Bioequivalence Study Between Levocetirizine Oral Disintegrating Tablet (ODT) and Levocetirizine Immediate Release Tablet (IRT) The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT03555890 Recruitment Status

2018 Clinical Trials

168. Phase I Study of GSK2982772 in Japanese Healthy Male Participants

Frame: Up to Day 39 ] The following hematology parameters will be analyzed: platelet count, red blood cell (RBC) count, hemoglobin, hematocrit, mean corpuscular volume (MCV), mean corpuscular hemoglobin (MCH), percent reticulocytes, neutrophils, lymphocytes, monocytes, eosinophils and basophils. Number of subjects with abnormal clinical chemistry parameters [ Time Frame: Up to Day 39 ] The following clinical chemistry parameters will be analyzed: blood urea nitrogen (BUN), creatinine, uric acid (...) of GSK2982772 in Japanese Healthy Male Participants The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT03590613 Recruitment Status : Completed First Posted : July 18, 2018 Last Update Posted : January 29, 2019 Sponsor: GlaxoSmithKline Information provided by (Responsible Party): GlaxoSmithKline Study Details

2018 Clinical Trials

169. To Assess the Impact of Ferric Carboxymaltose Compared With Iron Sucrose in Chinese Subjects on Correcting Iron Deficiency Anaemia

) at the screening visit Transferrin Saturation (TSAT) <16% (any subject) at the screening visit Microcytic, hypochromic anaemia defined as: a) Mean corpuscular Hb concentration (MCHC) <32%; b) Mean corpuscular volume (MCV) < 80 fL; c)Mean corpuscular Hb (MCH) <27 pg Subjects with the ability to understand the requirements of the study and abide by the study restrictions, and who agree to return for the required assessments Before any study-specific procedure is conducted, the appropriate written informed (...) reached the maximum number of saved studies (100). Please remove one or more studies before adding more. To Assess the Impact of Ferric Carboxymaltose Compared With Iron Sucrose in Chinese Subjects on Correcting Iron Deficiency Anaemia The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. of clinical studies and talk to your health care provider before

2018 Clinical Trials

170. Ferrous Acetyl-Aspartate Casein Formulation Evaluation Over Ferrous Sulfate in Iron Deficiency Anemia

for eligibility information Ages Eligible for Study: 18 Years and older (Adult, Older Adult) Sexes Eligible for Study: All Accepts Healthy Volunteers: No Criteria Inclusion Criteria: Male or female Age equal to or more than 18 years Written informed consent provided by the patient Hb below 10g/dl, as defined by other trials Absolute red blood cell (RBC) count below 4.5 x 106/mm3 for men or 4.0 x 106/mm3 for women Mean corpuscular volume (MCV) of RBCs below 80 fl Mean corpuscular Hb (MCH) of RBCs below 27 pg (...) remove one or more studies before adding more. Ferrous Acetyl-Aspartate Casein Formulation Evaluation Over Ferrous Sulfate in Iron Deficiency Anemia (ACCESS) The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. of clinical studies and talk to your health care provider before participating. Read our for details. ClinicalTrials.gov Identifier: NCT03524651

2018 Clinical Trials

171. Iron Parameters in Non-anemic First Trimester Gravidas

Task Force (USPSTF) stated "there is insufficient evidence to recommend the routine screening for iron deficiency in non-anemic gravidas". The basis for this recommendation is the lack maternal or fetal outcome data in this population. To date, there are no guidelines for the treatment of non-anemic, iron deficiency pregnancy women with or without anemia. Obstetricians and gynecologists often do not screen for iron deficiency unless the mean corpuscular volume (MCV) is reduced even in the presence (...) Gravidas The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT03670537 Recruitment Status : Completed First Posted : September 13, 2018 Results First Posted : October 15, 2018 Last Update Posted : October 15, 2018 Sponsor: Auerbach Hematology Oncology Associates P C Collaborator: MedStar Women's Care

2018 Clinical Trials

172. Phase 2b, Open-label, Multicenter, Rollover Study to Assess Antiviral Activity and Safety of Long-acting Cabotegravir (CAB LA) Plus Long-acting Rilpivirine (RPV LA), Administered Every 2 Months (Q2M), in Human Immunodeficiency Virus (HIV)- Positive Subjec

, whether or not considered related to the medicinal product. Number of subjects who will discontinue the treatment due to AEs will be reported. Number of subjects with abnormal hematology findings [ Time Frame: Up to 40 months ] Blood samples will be collected to measure platelets, white blood cell (WBC count), red blood cell (RBC) count, reticulocyte count, hemoglobin, hematocrit, RBC indices, mean corpuscular volume (MCV), basophils, eosinophils, lymphocytes, monocytes and neutrophils. Number (...) ) Plus Long-acting Rilpivirine (RPV LA), Administered Every 2 Months (Q2M), in Human Immunodeficiency Virus (HIV)- Positive Subjects From the LATTE Study The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. of clinical studies and talk to your health care provider before participating. Read our for details. ClinicalTrials.gov Identifier: NCT03639311 Recruitment

2018 Clinical Trials

173. A Study to Investigate the Pharmacokinetics of Modified Release (MR) Prototype Coated Tablet Formulations of GSK2982772

. Part A- Number of subjects with abnormal hematology parameters [ Time Frame: Up to 12 weeks ] Blood samples will be collected to measure platelets, white blood cell (WBC count), red blood cell (RBC) count, reticulocyte count, hemoglobin, hematocrit, RBC indices, mean corpuscular volume (MCV), mean corpuscular hemoglobin (MCH), mean corpuscular hemoglobin concentration (MCHC), basophils, eosinophil's, lymphocytes, monocytes and neutrophils. Part A- Number of subjects with abnormal urinalysis [ Time (...) number of saved studies (100). Please remove one or more studies before adding more. A Study to Investigate the Pharmacokinetics of Modified Release (MR) Prototype Coated Tablet Formulations of GSK2982772 The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. of clinical studies and talk to your health care provider before participating. Read our for details

2018 Clinical Trials

174. A Single Inhalation Dose Study to Assess Efficacy, Pharmacokinetics (PK), Safety and Tolerability of AZD8871 in Patients With Long-term Lung Diseases.

assessments: Haematology - Mean corpuscular volume (MCV) [ Time Frame: At screening, throughout the treatment periods till follow-up (42 days after visit 11 or last IP administration) or discontinuation. ] To assess MCV as a variable of safety and tolerability after administration of inhaled AZD8871 600 µg. Laboratory assessments: Haematology - Mean corpuscular hemoglobin (MCH) [ Time Frame: At screening, throughout the treatment periods till follow-up (42 days after visit 11 or last IP administration (...) ) or discontinuation. ] To assess MCH as a variable of safety and tolerability after administration of inhaled AZD8871 600 µg. Laboratory assessments: Haematology - Mean corpuscular hemoglobin concentration (MCHC) [ Time Frame: At screening, throughout the treatment periods till follow-up (42 days after visit 11 or last IP administration) or discontinuation. ] To assess MCHC as a variable of safety and tolerability after administration of inhaled AZD8871 600 µg. Laboratory assessments: Haematology - Differential

2018 Clinical Trials

175. Pilates Program in Female Adolescent With Eating Disorders

dispersion; transferrin saturation index. Changes in blood parameters measured in fL. [ Time Frame: 3 times (week 0, week 10, week 20). ] The following blood parameter measured in fL were analyzed: mean corpuscular volume. Changes in blood parameters measured in μg/dL [ Time Frame: 3 times (week 0, week 10, week 20). ] The following blood parameter measured in μg/dL were analyzed: iron. Changes in blood parameters measured in mmol/L. [ Time Frame: 3 times (week 0, week 10, week 20). ] The following blood (...) ; hemoglobin; mean corpuscular hemoglobin concentration. Changes in blood parameters measured in 10^3/μL. [ Time Frame: 3 times (week 0, week 10, week 20). ] The following blood parameters measured in 10^3/μL were analyzed: platelets; red blood cells; leukocytes; lymphocytes; neutrophils; monocytes; basophils; eosinophils. Changes in blood parameters measured in % [ Time Frame: 3 times (week 0, week 10, week 20). ] The following blood parameters measured in % were analyzed: hematocrit; red blood cell

2018 Clinical Trials

176. An Early Bactericidal Activity, Safety and Tolerability of GSK3036656 in Subjects With Drug-sensitive Pulmonary Tuberculosis

with abnormal findings for hematology parameters [ Time Frame: Up to 28 days ] Blood samples will be collected from subjects for the analysis of hematology parameters as a measure of safety, including platelet count, mean corpuscular volume, mean corpuscular hemoglobin, percent reticulocytes, neutrophils, lymphocytes, monocytes, eosinophil's, basophils, red blood cells count, hemoglobin, and hematocrit coagulation test. Number of subjects with abnormal findings for urinalysis parameters [ Time Frame: Up (...) the maximum number of saved studies (100). Please remove one or more studies before adding more. An Early Bactericidal Activity, Safety and Tolerability of GSK3036656 in Subjects With Drug-sensitive Pulmonary Tuberculosis The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. of clinical studies and talk to your health care provider before participating. Read our

2018 Clinical Trials

177. Open-label Comparison of Chronocort® Versus Standard Glucocorticoid Replacement Therapy

) between the Chronocort arm and Standard Care arm. Safety of Chronocort® compared to standard care by assessment of routine safety haematology assessments - mean corpuscular volume (MCV) [ Time Frame: Baseline (Day 1), Week 2, Week 6, Week 12, Week 26, Week 39 & Week 52 ] Routine haematology assessments to compare mean corpuscular volumes (volume of red blood cells) between the Chronocort arm and Standard Care arm. Safety of Chronocort® compared to standard care by assessment of routine safety (...) before adding more. Open-label Comparison of Chronocort® Versus Standard Glucocorticoid Replacement Therapy (RESTORE) The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT03532022 Recruitment Status : Suspended (Protocol re-design required following inconclusive EU Phase III results) First Posted : May 22

2018 Clinical Trials

178. Pro-arrhythmic Potential of GSK3039294 in Healthy Subjects

will be collected for assessment of hematology parameters including platelet count, red blood cell count (RBC), hemoglobin, hematocrit, mean corpuscular volume, mean corpuscular hemoglobin, percentage of reticulocytes, neutrophils, lymphocytes, monocytes, eosinophil's and basophils. Number of subjects with abnormal hematology parameters: Part B [ Time Frame: Up to 35 days ] Blood samples will be collected for assessment of hematology parameters including platelet count, RBC, hemoglobin, hematocrit, mean (...) corpuscular volume, mean corpuscular hemoglobin, percentage of reticulocytes, neutrophils, lymphocytes, monocytes, eosinophil's and basophils. Number of subjects with abnormal clinical chemistry parameters: Part A [ Time Frame: Up to 49 days ] Blood samples will be collected for the assessment of clinical chemistry parameters blood urea nitrogen, creatinine, glucose fasting, potassium, sodium, calcium, aspartate aminotransferase, alanine aminotransferase, alkaline phosphatase, total and direct bilirubin

2018 Clinical Trials

179. A Study to Evaluate the Efficacy of Salmon Protein Hydrolysate Powder on Energy Increase and Anti-inflammatory Modulation in Healthy Males and Females

to Day 128 in Mean corpuscular volume (MCV) after supplementation with Salmon Protein Hydrolysate Powder (CollaGo®) [ Time Frame: Baseline (Day 0) to end-of-study (Day 128) ] Change from baseline to Day 128 in mean corpuscular hemoglobin (MCH) after supplementation with Salmon Protein Hydrolysate Powder (CollaGo®) [ Time Frame: Baseline (Day 0) to end-of-study (Day 128) ] Change from baseline to Day 128 in mean corpuscular hemoglobin concentration (MCHC) after supplementation with Salmon Protein (...) Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. A Study to Evaluate the Efficacy of Salmon Protein Hydrolysate Powder on Energy Increase and Anti-inflammatory Modulation in Healthy Males and Females The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our

2018 Clinical Trials

180. A Safety and Efficacy Study of Mepolizumab in Subjects With Severe Asthma

parameters [ Time Frame: Up to Week 52 ] Hematology parameters which will be assessed include platelet count, red blood cell (RBC) count, hemoglobin, hematocrit; RBC indices: mean corpuscular volume (MCV), mean corpuscular hemoglobin (MCH); white blood cell (WBC) count with differential: neutrophils, lymphocytes, monocytes, eosinophils and basophils. Number of subjects with abnormal clinical chemistry parameters [ Time Frame: Up to Week 52 ] Clinical chemistry parameters which will be assessed include (...) Frame: Up to Week 52 ] An exacerbation is defined as worsening of asthma requiring the use of systemic corticosteroids and/or emergency department visit, or hospitalization. Mean change from Baseline in clinic prebronchodilator forced expiratory volume in 1 second (FEV1) at Week 52 [ Time Frame: Baseline and Week 52 ] FEV1 is the volume of air that can be forced out in one second after taking a deep breath. FEV1 will be measured via spirometer at Baseline and Week 52. Number of subjects with adverse

2018 Clinical Trials

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>